mTORC1选择性抑制剂在TSC iPSC衍生的神经元中拯救细胞表型
Elizabeth D Buttermore1,2, Gayathri Rajaram Srinivasan1,2, Hellen Jumo2,3
1Human Neuron Core, Rosamund Stone Zander Translational Neuroscience Center, Boston Children's Hospital, Boston, MA, United States.
Frontiers in neuroscience
|August 12, 2025
概括
选择性mTORC1抑制剂逆转了结核性硬化综合体 (TSC) 患者神经元中的神经学缺陷. 这些化合物提供了类似于拉帕米辛的潜在治疗益处,但副作用较少.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 拉巴胺素 (mTOR) 途径的机械性标调节了关键的细胞功能.
- mTOR通路的调节失调与诸如结核性硬化综合体 (TSC) 等神经系统疾病有关.
- TSC与TSC1或TSC2基因的突变相关,影响mTOR活动.
研究的目的:
- 调查新型mTORC1选择性抑制剂是否可以逆转TSC患者衍生的神经元中的细胞和功能缺陷.
- 在TSC模型中比较mTORC1选择性抑制剂与拉帕素的疗效.
- 探索TSC的潜在治疗策略,减少副作用.
主要方法:
- 利用来自TSC患者 (TSC2-/-) 的诱导多能干细胞 (iPSC) 衍生神经元.
- 用新型mTORC1-选择性化合物和拉巴胺素治疗的神经元.
- 评估了神经元形态和过度兴奋现象型.
主要成果:
- mTORC1-选择性抑制剂有效地逆转了TSC2-/- iPSC衍生神经元中的神经元过激和异常形态.
- 对于mTORC1抑制剂的影响,其大小和方式与拉帕米辛治疗相似.
- 这些发现表明mTORC1信号在TSC相关的神经元功能障碍中起着关键作用.
结论:
- 选择性抑制mTORC1可以使TSC患者衍生的神经元中的细胞和功能缺陷正常化.
- 与非选择性mTOR抑制剂相比,mTORC1特异性化合物可能为TSC提供一种治疗方法,与非选择性mTOR抑制剂相比,其副作用配置有所改善.
- 针对mTORC1为未来的TSC治疗提供了一个有希望的途径.
相关概念视频
iPS Cell Differentiation
2.8K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.8K
Induced Pluripotent Stem Cells
4.4K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
4.4K


